<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01248195</url>
  </required_header>
  <id_info>
    <org_study_id>KP7242114</org_study_id>
    <secondary_id>2010-020185-19</secondary_id>
    <nct_id>NCT01248195</nct_id>
  </id_info>
  <brief_title>Optimization of Treatment and Management of Schizophrenia in Europe</brief_title>
  <acronym>OPTIMISE</acronym>
  <official_title>Optimization of Treatment and Management of Schizophrenia in Europe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rene Kahn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Manchester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is optimising current treatments in schizophrenia and explore novel
      therapeutic options for schizophrenia. The study intends to both address basic, but so far
      unanswered, questions in the treatment of schizophrenia and develop new interventions. It is
      expected that the project will lead to evidence that is directly applicable to treatment
      guidelines, and will identify potential mechanisms for new drug development.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite nearly fifty years of pharmacological and psychosocial research, the overall
      prognosis of schizophrenia has improved only marginally. While the efficacy of most
      antipsychotic medication is generally uncontested, their overall functional impact has been
      modest. In order to improve this unsatisfactory result, this study aims to optimize current
      treatments in schizophrenia and explore novel therapeutic options for schizophrenia. The
      study comprises a medication intervention component, a psychosocial intervention component, a
      biological predictor component and an MRI component. MRI assessments are performed at
      baseline, and used to determine whether potential organic causes for psychotic symptoms are
      present, and to test prospective value of these assessments for subsequent treatment
      response. MRI assessments of healthy volunteers will be included to test for deviations in
      patients' assessments; these volunteers will not participate in any other protocol procedure.
      The medication intervention component comprises a first 4-week phase of amisulpride
      treatment. Non-responders will subsequently be randomised to a 6-week double blind phase on
      either amisulpride or olanzapine. Patients who classify as non-responders at the end of this
      phase, a 12-week open label treatment with clozapine is initiated. Patients who classify as a
      responder in phase I, II or III, are drop outs or who are non-responders at the end of phase
      III flow to the psychosocial intervention component of the study. During this part, several
      interventions are tested, aimed to increase treatment compliance and keep patients on the
      medication to which they've responded well. Through the biological predictor component, it is
      determined whether glutamatergic markers predict response to first and second line
      treatments, and if an empirical combination of pharmacogenetic, proteomics- and metabolomic
      markers can provide clinical valuable predictive value.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PANSS</measure>
    <time_frame>Jan 2016</time_frame>
    <description>Study consists of multiple components, each with their own objectives. For this (medication) component: number of patients in remission, based on PANSS scores (criteria of Andreasen et al.; 2005) after 4 weeks open label amisulpride, after 6 weeks double blind amisulpride or olanzapine and after 12 weeks of open label clozapine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sellwood rating scale</measure>
    <time_frame>Jan 2016</time_frame>
    <description>Psychosocial intervention component, objective A: drug adherence rates as a function of (standardized self report and) Sellwood rating scales after 12 and 52 weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biological profile</measure>
    <time_frame>jan 2016</time_frame>
    <description>Biological predictors component, objective A: drug response (remission vs non-remission) as a function of biological profile, after 4 weeks, 10 weeks and 22 weeks (after each medication phase).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRS measures</measure>
    <time_frame>jan 2016</time_frame>
    <description>Biological predictors component, objective B: using MRS scans, differences between responders and non-responders in regional glutamate levels a) at baseline and b) between baseline and after one month of treatment with amisulpiride.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SOFAS global functioning</measure>
    <time_frame>jan 2016</time_frame>
    <description>Psychosocial intervention component, objective B: drug adherence rates as a function of standardized global functioning (SOFAS score after 1 year) following psychosocial intervention vs treatment as usual.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRI assessments</measure>
    <time_frame>jan 2016</time_frame>
    <description>MRI component objective: the percentage of first episode patients that show radiological abnormalities suggestive of neurological disorders which may explain the occurrence of psychotic symptoms - measurement at baseline only.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause treatment discontinuation</measure>
    <time_frame>jan 2016</time_frame>
    <description>The different components of the study have their own secondary objectives:
Medication component has multiple secondary objectives, most important one is all-cause treatment discontinuation after 4 weeks, 10 weeks and 22 weeks. Number and reason for premature discontinuations (treatment discontinuation) of the amisulpride and the olanzapine group will be compared (after 10 weeks).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause discontinuation</measure>
    <time_frame>jan 2016</time_frame>
    <description>Psychosocial intervention component has multiple secondary objectives, most important one is all-cause treatment discontinuation between treatment groups after 12 and 52 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological markers</measure>
    <time_frame>jan 2016</time_frame>
    <description>Biological predictors component has multiple secondary objectives, most important one is the ability of biological markers to predict response to antipsychotic and treatment tolerability in schizophrenia, after 4, 10 and 22 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI assessments</measure>
    <time_frame>jan 2016</time_frame>
    <description>The ability of MRI to predict response to antipsychotic treatment in schizophrenia, after 4, 10 and 22 weeks.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">479</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizophreniform Disorder</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>Phase I: 1 arm 'amisulpride open label'</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>For 4 weeks, all patients will be treated with amisulpride open label.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: 'amisulpride double blind'</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who do not meet remission criteria during phase I (4 weeks open label amisulpride), flow to phase II where they are randomised to 1 of 2 6-week double blind treatment arms, one of which is 'amisulpride double blind'</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II 'olanzapine double blind'</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who do not meet remission criteria during phase I (4 weeks open label amisulpride), flow to phase II where they are randomised to 1 of 2 6-week double blind treatment arms, one of which is 'olanzapine double blind'</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase III: 1 arm 'clozapine open label'</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who do not meet remission criteria during phase II (6-week double blind amisulpride vs olanzapine), flow to phase III, where only 1 arm is available: 'clozapine open label'</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Psychosocial intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who meet remission criteria during any of the phases of the medication component, patients who drop out of the medication component and patients who did not meet remission criteria at the end of the medication component, will flow to the psychosocial intervention component, where they are randomised to 1 of 2 arms, one of which is the 'Psychosocial Intervention' arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Psychosocial Intervention phase: 'TAU'</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients who meet remission criteria during any of the phases of the medication component, patients who drop out of the medication component and patients who did not meet remission criteria at the end of the medication component, will flow to the psychosocial intervention component, where they are randomised to 1 of 2 arms, one of which is the 'Treatment as usual' arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amisulpride open label</intervention_name>
    <description>4-week open label amisulpride treatment</description>
    <arm_group_label>Phase I: 1 arm 'amisulpride open label'</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6-week amisulpride double blind treatment</intervention_name>
    <description>6-week amisulpride double blind treatment</description>
    <arm_group_label>Phase II: 'amisulpride double blind'</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6-week olanzapine double blind treatment</intervention_name>
    <description>6-week olanzapine double blind treatment</description>
    <arm_group_label>Phase II 'olanzapine double blind'</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>12-week clozapine open-label treatment</intervention_name>
    <description>12-week clozapine open-label treatment</description>
    <arm_group_label>Phase III: 1 arm 'clozapine open label'</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Psychosocial intervention</intervention_name>
    <description>Psychosocial intervention</description>
    <arm_group_label>Psychosocial intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of schizophrenia as defined by DSM-IV-R as determined by the M.I.N.I.plus

          2. Age 18 or older.

          3. The first psychosis occurred at least one year and no more than 7 years ago.*

          4. If patients are using an antipsychotic drug, a medication switch is currently under
             consideration.

          5. Capable of providing written informed consent.

        Exclusion Criteria:

          1. Intolerance / hypersensitivity to one of the drugs (including active substances,
             metabolites and excipients) in this study including oral risperidone, paliperidone and
             aripiprazole and/or hypersensitivity to risperidone.

          2. Pregnancy or lactation.

          3. Patients who are currently using clozapine.

          4. Patients who do not fully comprehend the purpose or are not competent to make a
             rational decision whether or not to participate.

          5. Patients with a documented history of non-response and/or intolerance to any of the
             study medications and/or a documented history of non-response to a treatment with one
             of the study drugs of at least 6 weeks within the registered dose range.

          6. Forensic patients.

          7. Patients who have been treated with an investigational drug within 30 days prior to
             screening.

          8. Simultaneous participation in another intervention study (neither medication or
             psychosocial intervention).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>René Kahn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Utrecht, the Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Melbourne Neuropsychiatry Centre</name>
      <address>
        <city>Melbourne</city>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Biological Psychiatry, Innsbruck University Clinics</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katholieke Universiteit Leuven (KU Leuven)</name>
      <address>
        <city>Leuven</city>
        <zip>B - 3070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Specialised Hospital for Active Treatment in Neurology and Psychiatry &quot;St. Naum&quot;</name>
      <address>
        <city>Sofia</city>
        <zip>1113</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatrické centrum Praha</name>
      <address>
        <city>Prague</city>
        <state>Ustavni 91</state>
        <zip>181 03 Praha 8-Bohnice</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatrická klinika LF UK, Fakultní nemocnice</name>
      <address>
        <city>Hradec Králové</city>
        <zip>CZ - 500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Neuropsychiatric Research</name>
      <address>
        <city>Glostrup</city>
        <zip>DK-2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut National de la Santé et de la Reserche Médicale (INSERM)</name>
      <address>
        <city>Créteil Cedex</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin-Luther-University (MLU) of Halle-Wittenberg</name>
      <address>
        <city>Halle</city>
        <zip>06097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deprtment of Psychiatry, University of Heidelberg</name>
      <address>
        <city>Mannheim</city>
        <zip>J 5, D-68159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilians University München</name>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Technische Universität München (TUM)</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Centre Department of Psychiatry</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry University of Naples</name>
      <address>
        <city>Naples</city>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Adult Psychiatry, University of Medical Sciences</name>
      <address>
        <city>Poznan</city>
        <zip>60-572</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Obregia Psychiatric Hospital</name>
      <address>
        <city>Bucuresti</city>
        <zip>7000</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036 Barcelona</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicio Madrileño de Salud (SERMAS)</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040 Madrid</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigación Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041 Madrid</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidad de Oviedo</name>
      <address>
        <city>Oviedo</city>
        <zip>33011 Oviedo</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clienia Schlössli AG, Privatklinik für Psychiatrie und Psychotherapie</name>
      <address>
        <city>Oetwil am See</city>
        <zip>CH-8618</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College London, Departments of Psychological Medicine, Psychiatry &amp; Cognitive Neuroscience</name>
      <address>
        <city>London</city>
        <zip>SE5 8AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West London Mental Health Trust</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Manchester</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.optimisetrial.eu</url>
    <description>Study website</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2010</study_first_submitted>
  <study_first_submitted_qc>November 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2010</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Rene Kahn</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Schizophreniform disorder</keyword>
  <keyword>Schizoaffective disorder</keyword>
  <keyword>Imaging</keyword>
  <keyword>Prognosis</keyword>
  <keyword>Treatment guidelines</keyword>
  <keyword>Pharmacogenetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Clozapine</mesh_term>
    <mesh_term>Sultopride</mesh_term>
    <mesh_term>Sulpiride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

